Jim Richey has become a senior advisor of business development, and Charles Campbell a member of the scientific advisory board of Lumera, the Bothell, Wash.-based company said last month.
Richey has held senior executive positions at LJL BioSystems, PerSeptive BioSystems, Pharmacia Biosensor, and Pharmacia Biotech.
Campbell is a professor of chemistry at the University of Washington and a co-director of the University of Washington/PNNL Joint Institute for Nanotechnology.
Pieter Muntendam has become the new president of BG Medicine, formerly Beyond Genomics, the systems biology firm announced last week.
Muntendam has previously held senior executive positions at Glaxo Wellcome (now GlaxoSmithKline), Johnson & Johnson, NetNumina, Organon International and others.
He received his MD from Leiden University in The Netherlands.
Daniel Von Hoff and Raymond Woosley have joined the scientific advisory board of HTG the gene expression assay-technology and services company said this week.
Von Hoff was named to the National Cancer Advisory Board in 2004 and has held positions at the American Association for Cancer Research, the American College of Physicians, and the American Society of Clinical Oncology. He is a founder of ILEX Oncology, which was recently acquired by Genzyme.
Woosley recently became president of the Critical Path Institute and has held administrative positions at the University of Arizona and Georgetown University.